FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2219-2223 May 24, 2007 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: In his Perspective article on diabetes, Nathan (Feb. 1 issue)¹ suggests that a newly approved dipeptidyl peptidase IV (DPP-IV) inhibitor, sitagliptin, "is one of the less effective glycemia-lowering drugs." This contention may reflect a misunderstanding of the relationship between a change in the glycated hemoglobin level and the baseline value. Our meta-analysis showed that for existing oral agents, with a baseline glycated hemoglobin level between 9.0% and 9.9%, the mean decrease was 1.0 percentage point, whereas for a baseline level between 8.0% and 8.9%, the mean decrease was 0.6 percentage point.² The smaller decreases in the glycated . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.